Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.

Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R.

Oncologist. 2018 Aug;23(8):943-947. doi: 10.1634/theoncologist.2018-0028. Epub 2018 Apr 5.


Lagged cumulative spruce budworm defoliation affects the risk of fire ignition in Ontario, Canada.

James PM, Robert LE, Wotton BM, Martell DL, Fleming RA.

Ecol Appl. 2017 Mar;27(2):532-544. doi: 10.1002/eap.1463. Epub 2017 Feb 22.


National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Gea-Banacloche J, Komanduri KV, Carpenter P, Paczesny S, Sarantopoulos S, Young JA, El Kassar N, Le RQ, Schultz KR, Griffith LM, Savani BN, Wingard JR.

Biol Blood Marrow Transplant. 2017 Jun;23(6):870-881. doi: 10.1016/j.bbmt.2016.10.001. Epub 2016 Oct 14. Review.


CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation.

Anand A, Anandi P, Jain NA, Lu K, Dunavin N, Hourigan CS, Le RQ, Chokshi PD, Ito S, Stroncek DF, Sabatino M, Barrett AJ, Battiwalla M.

Support Care Cancer. 2016 Feb;24(2):815-822. doi: 10.1007/s00520-015-2848-9. Epub 2015 Jul 21.


Minor ABO Incompatibility Does Not Impact Nonrelapse Mortality in T Cell-Depleted Human Leukocyte Antigen-Matched Sibling Transplantation.

Chokshi P, Anandi P, Jain N, Dunavin N, Le RQ, Ito S, Barrett J, Battiwalla M.

Biol Blood Marrow Transplant. 2015 May;21(5):954-5. doi: 10.1016/j.bbmt.2015.02.020. Epub 2015 Feb 21. No abstract available.


Clinical and biological predictors of outcome following relapse of CML post-allo-SCT.

Jain NA, Ito S, Tian X, Kurlander R, Battiwalla M, Lu K, Savani BN, Malkovska V, Rezvani K, Le RQ, Shenoy A, Hourigan CS, Keyvanfar K, Koklanaris E, Superata J, Muranski P, Barrett AJ, Yong ASM.

Bone Marrow Transplant. 2015 Feb;50(2):189-196. doi: 10.1038/bmt.2014.249. Epub 2014 Nov 10.


Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events.

Pophali PA, Klotz JK, Ito S, Jain NA, Koklanaris E, Le RQ, Hourigan CS, Savani BN, Chawla K, Shanbhag S, Barrett AJ, Battiwalla M.

Exp Hematol. 2014 Feb;42(2):83-9. doi: 10.1016/j.exphem.2013.07.003. Epub 2013 Oct 17.


Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy.

Rezvani K, Yong AS, Mielke S, Savani BN, Jafarpour B, Eniafe R, Le RQ, Musse L, Boss C, Childs R, John Barrett A.

Cancer Immunol Immunother. 2012 Jul;61(7):1125-36. doi: 10.1007/s00262-011-1187-z. Epub 2011 Dec 24.


Evolution of the donor T-cell repertoire in recipients in the second decade after allogeneic stem cell transplantation.

Le RQ, Melenhorst JJ, Battiwalla M, Hill B, Memon S, Savani BN, Shenoy A, Hensel NF, Koklanaris EK, Keyvanfar K, Hakim FT, Douek DC, Barrett AJ.

Blood. 2011 May 12;117(19):5250-6. doi: 10.1182/blood-2011-01-329706. Epub 2011 Mar 18.


Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.

Rezvani K, Yong AS, Mielke S, Jafarpour B, Savani BN, Le RQ, Eniafe R, Musse L, Boss C, Kurlander R, Barrett AJ.

Haematologica. 2011 Mar;96(3):432-40. doi: 10.3324/haematol.2010.031674. Epub 2010 Dec 6.


Favorable outcomes in patients surviving 5 or more years after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Le RQ, Bevans M, Savani BN, Mitchell SA, Stringaris K, Koklanaris E, Barrett AJ.

Biol Blood Marrow Transplant. 2010 Aug;16(8):1162-70. doi: 10.1016/j.bbmt.2010.03.005. Epub 2010 Mar 17.

Supplemental Content

Loading ...
Support Center